Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacira Biosciences, Inc. on October 6, 2023, with the earliest event reported on that date. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of new members.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- The Board size was increased from 10 to 12 directors.
- Four new directors were appointed effective immediately: Alethia Young (Class II), Marcelo Bigal (Class II), Abraham Ceesay (Class III), and Michael Yang (Class I).
- All four appointees were determined to be independent directors under Nasdaq listing standards.
Committee Assignments and Compensation
The new directors were assigned to specific board committees:
- Alethia Young: Audit Committee.
- Marcelo Bigal: Science and Technology Committee.
- Abraham Ceesay: Compensation Committee.
- Michael Yang: Compensation Committee.
Each new director will receive the Company's standard compensation for non-employee directors. No related party transactions or special understandings regarding their selection were reported.
Investor Verification Checklist
- Verify the independence status of the four new directors against Nasdaq listing standards.
- Review the press release dated October 10, 2023 (Exhibit 99.1) for additional biographical details on the new appointees.
- Confirm the standard compensation package for non-employee directors in the Company's proxy statement or prior filings.
- Note that this filing contains no financial updates; refer to the most recent 10-Q or 10-K for financial metrics.